Related Experiment Video
Updated: Mar 31, 2026

Fixation and Operational Method for Abdominal Massage in T2DM Mice
Published on: March 7, 2025
Interrupting Sitting Time with Regular Walks Attenuates Postprandial Triglycerides
M Miyashita1, K Edamoto1, T Kidokoro1
1Department of Health and Sports Sciences, Tokyo Gakugei University, Koganei, Japan.
Regularly interrupting prolonged sitting with brief walking breaks significantly lowers postprandial triglyceride levels in postmenopausal women. This simple strategy improves metabolic health by reducing harmful blood fats after meals.
Area of Science:
- Exercise Physiology
- Metabolic Health
- Cardiovascular Disease Prevention
Background:
- Prolonged sitting is linked to adverse metabolic outcomes, including elevated postprandial triglycerides.
- Postmenopausal women are particularly susceptible to metabolic changes and cardiovascular risks.
Purpose of the Study:
- To compare the effects of prolonged sitting versus interrupted sitting with walking on postprandial triglyceride levels in postmenopausal women.
- To evaluate the impact of regular short walking bouts versus a single longer bout on metabolic markers.
Main Methods:
- 15 postmenopausal women participated in three randomized trials: prolonged sitting, regular walking breaks, and sitting after continuous walking.
- Participants consumed standardized meals, and blood samples were collected over 8 hours to measure serum triglyceride levels.
- Walking interventions involved either brief, frequent bouts or one morning session.
Main Results:
- Regularly interrupting sitting with walking significantly reduced the incremental area under the curve for serum triglycerides by 15% and 14% compared to prolonged sitting.
- No significant difference was observed between prolonged sitting and sitting after a continuous morning walk.
Conclusions:
- Intermittent physical activity, specifically regular short walking bouts, is effective in mitigating postprandial lipemia in postmenopausal women.
- Strategies to break up sedentary time are crucial for improving metabolic health and potentially reducing cardiovascular risk in this population.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Atherosclerosis III: Management
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Hypoglycemia and Glucagon
Peripheral Artery Disease III: Interprofessional Care

